文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Pyrrolidine Compounds as Potential Lipid-Lowering Therapeutic in Cardiovascular Disease.

作者信息

Kargbo Robert B

机构信息

Usona Institute, 277 Granada Drive, San Luis Obispo, California 93401-7337, United States.

出版信息

ACS Med Chem Lett. 2021 Mar 16;12(4):521-523. doi: 10.1021/acsmedchemlett.1c00121. eCollection 2021 Apr 8.

DOI:10.1021/acsmedchemlett.1c00121
PMID:33859785
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8040050/
Abstract
摘要

相似文献

[1]
Pyrrolidine Compounds as Potential Lipid-Lowering Therapeutic in Cardiovascular Disease.

ACS Med Chem Lett. 2021-3-16

[2]
Observational study of patients from a Lipid Unit on lipid-modifying therapy for primary and secondary prevention: ULFI Study.

Clin Investig Arterioscler. 2023

[3]
Efficacy of more intensive lipid-lowering therapy on cardiovascular diseases: a systematic review and meta-analysis.

BMC Cardiovasc Disord. 2020-7-13

[4]
Cholesterol-Lowering Effects of Asperidine B, a Pyrrolidine Derivative from the Soil-Derived Fungus PSU-RSPG178: A Potential Cholesterol Absorption Inhibitor.

Pharmaceuticals (Basel). 2022-7-31

[5]
The Expected 30-Year Benefits of Early Versus Delayed Primary Prevention of Cardiovascular Disease by Lipid Lowering.

Circulation. 2020-9

[6]
Comparison of the European and US guidelines for lipid-lowering therapy in primary prevention of cardiovascular disease.

Eur J Prev Cardiol. 2023-11-30

[7]
Induction of cell killing and autophagy by amphiphilic pyrrolidine derivatives on human pancreatic cancer cells.

Eur J Med Chem. 2018-4-25

[8]
Lipid-lowering drug use and cardiovascular events after myocardial infarction.

Ann Pharmacother. 2002-5

[9]
Drug treatment of hyperlipidemia in women.

JAMA. 2004-5-12

[10]
Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.

High Blood Press Cardiovasc Prev. 2016-9

本文引用的文献

[1]
More purinergic receptors deserve attention as therapeutic targets for the treatment of cardiovascular disease.

Am J Physiol Heart Circ Physiol. 2020-8-21

[2]
Lipoprotein(a): Expanding our knowledge of aortic valve narrowing.

Trends Cardiovasc Med. 2021-7

[3]
Lipid lowering therapy in cardiovascular disease: From myth to molecular reality.

Pharmacol Ther. 2020-9

[4]
Antisense lipoprotein[a] therapy: State-of-the-art and future perspectives.

Eur J Intern Med. 2020-6

[5]
Recent advances in genome editing for cardiovascular disease.

Curr Opin Cardiol. 2020-5

[6]
Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.

J Intern Med. 2020-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索